anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Lidocaine
Trial phase: Phase 4
ATC code: C01BB01 | C05AD01 | D04AB01 | N01BB02 | N01BB52 | R02AD02 | S01HA07 | S02DA01
SMILES: CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 77
Group description: Intravenous lidocaine 120 mg. A second dose can be administered at 30 minutes

Lidocaine: Lidocaine intravenous infusion
Eligibility criteria:
Inclusion Criteria:Eligible patients are those who present to an ED for treatment of acute abdominal pain. Acute will be defined as pain for no more than seven days. At the time of enrollment, the ED treatment plan must include use of an intravenous opioid.

Exclusion Criteria: Patients will be excluded from participation if they have cardiac conduction system impairment (QTc duration > 0.5s, QRS duration > 0.12s, or PR interval duration > 0.2s), known renal (CKD >2) or liver disease (Childs-Pugh B or greater), are hemodynamically unstable, as determined by the attending physician, are pregnant or breastfeeding, or have a known allergy to either medication. Patients will also be excluded if they have used prescription or illicit opioids within the previous week, or if they have a chronic pain disorder, defined as use of any analgesic medication on more days than not during the month preceding the acute episode of pain. Patients weighing < 60kg or > 120kg will be excluded.

-
Intervention: Carbamide Peroxide
Trial phase: Phase 2
SMILES: NC(N)=O.OO
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 15
Group description: The control group will consists of women with no imaging evidence of gynecological cancer, who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=6

PSMA-based 18F-DCFPyL PET tracer: PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer
Eligibility criteria:
Inclusion Criteria for healthy female controls N=12 (includes up to 6 Dosimetry participants):

Women with no suspected gynecological cancer.
No contraindications for MR or PET imaging.
Greater than or equal to 18 years of age.
Scheduled to undergo a hysterectomy and/or salpingo-oophorectomy

Inclusion Criteria for female controls (Dosimetry):

Women with or without suspected gynecological cancer.
No contraindications for MR or PET imaging.
Greater than or equal to 18 years of age.

Inclusion Criteria for gynecological cancer patients (N=40):

Women with known or suspected gynecological cancer
No contraindications for MR or PET imaging.
Greater than or equal to 18 years
Have had or are scheduled to undergo a hysterectomy and/or salpingo-oophorectomy

Exclusion Criteria:

Women that are pregnant or breast-feeding.
Age <18
Inability to provide informed consent on their own behalf
Severe kidney dysfunction (GFR <30 mL/min/1.73m2)
Intervention: Carbamide Peroxide
Trial phase: Phase 2
SMILES: NC(N)=O.OO
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 15
Group description: The patient group will consist of women with suspected gynecological cancers who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive standard of care PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=40

PSMA-based 18F-DCFPyL PET tracer: PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer
Eligibility criteria:
Inclusion Criteria for healthy female controls N=12 (includes up to 6 Dosimetry participants):

Women with no suspected gynecological cancer.
No contraindications for MR or PET imaging.
Greater than or equal to 18 years of age.
Scheduled to undergo a hysterectomy and/or salpingo-oophorectomy

Inclusion Criteria for female controls (Dosimetry):

Women with or without suspected gynecological cancer.
No contraindications for MR or PET imaging.
Greater than or equal to 18 years of age.

Inclusion Criteria for gynecological cancer patients (N=40):

Women with known or suspected gynecological cancer
No contraindications for MR or PET imaging.
Greater than or equal to 18 years
Have had or are scheduled to undergo a hysterectomy and/or salpingo-oophorectomy

Exclusion Criteria:

Women that are pregnant or breast-feeding.
Age <18
Inability to provide informed consent on their own behalf
Severe kidney dysfunction (GFR <30 mL/min/1.73m2)
Intervention: Phenazopyridine
Trial phase: Phase 4
ATC code: G04BX06
SMILES: Nc1ccc(/N=N/c2ccccc2)c(N)n1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 98
Group description: Phenazopyridine 200mg tablet, once prior to surgery
Eligibility criteria:
Inclusion Criteria:

Any female patient undergoing a midurethral sling surgery, regardless of concomitant pelvic reconstructive or gynecological surgery

Exclusion Criteria:

Patients with complications from surgery requiring indwelling catheter, bladder/urethral perforation requiring indwelling catheter
Acute bleeding requiring indwelling catheter for accurate urine output calculation
Patients undergoing concomitant surgery other than gynecological, preoperative voiding dysfunction defined as postvoid residual >150cc, or spinal anesthesia
Women who are pregnant, including women of childbearing age who test positive on preoperative urine pregnancy test
Intervention: Glutathione
Trial phase: Phase 3
ATC code: V03AB32
SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: 0.25% bupivacaine in patients undergoing total knee arthroplasty

0.25% bupivacaine: 0.25% bupivacaine in patients undergoing total knee arthroplasty
Eligibility criteria:
Inclusion Criteria:

All patients undergoing unilateral total knee replacement due to OA or rheumatoid arthritis
Ages 40- 80 years old
American Society of Anesthesiologists class I-III

Exclusion Criteria:

Refusal or absolute medical contraindication to peripheral nerve block
refusal or absolute medical contraindication to spinal anesthesia
conversion of spinal anesthesia to general anesthesia is obtained
inability to cooperate
allergy to any drug used in this study
daily intake of opioids (tramadol, morphine, oxycodone, methadone, fentanyl)
alcohol dependence or use of any illegal drugs within the last month
inability to perform the mobilization test and timed up and go (TUG) test pre-operatively
Intervention: (4-(2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamido)-2-oxopyridin-1(2H)-yl)methyl dihydrogen phosphate
Trial phase: Phase 2
SMILES: Cc1cc(F)ccc1Oc1cc(C(F)(F)F)ccc1C(=O)Nc1ccn(COP(=O)(O)O)c(=O)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 46
Group description: Participants received VX-150 1250 mg qd for 6 weeks.
Eligibility criteria:
Inclusion Criteria:

Body mass index (BMI) of 18.0 to 31.0 kg/m2, inclusive, and a total body weight >50 kg
Diagnosis of small fiber neuropathy, as per European Federation Neurological Societies (EFNS)/American Academy of Neurology (AAN) guidelines, with pain for at least 3 months prior to screening
Reduction below the 5th percentile of sex and age-adjusted normal values in epidermal nerve fiber density on punch skin biopsy at the distal site of the leg performed at screening
Normal nerve conduction studies (NCS), including presence of sural response.
Average NRS score between ≥4 and ≤9 reported in the daily diary on Days -7 through -1

Exclusion Criteria:

History in the past 10 years of malignancy except for squamous cell skin cancer, basal cell skin cancer, and Stage 0 cervical carcinoma in situ
History of connective tissue disorders, sarcoidosis, Sjögren's syndrome, amyloidosis, Fabry's disease, celiac disease, lyme disease, autoimmune disorders
A known or clinically suspected infection with human immunodeficiency virus or hepatitis B or C viruses
Current clinically significant liver or kidney dysfunction
Current uncontrolled thyroid dysfunction
A diagnosis of diabetes, HbA1C ≥8% at screening
History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)
Concomitant severe pain conditions which may impair self-assessment of pain due to small fiber neuropathy

Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: Budesonide
Trial phase: Phase 2
ATC code: A07EA06 | D07AC09 | R01AD05 | R03AK07 | R03AK12 | R03AL11 | R03BA02
SMILES: CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C)C4C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Budesonide EC 3 mg capsule. The dose will be as follows

Time post Liver Transplantation Immunosuppressive therapy Days 0-3 Standard immune suppression (SIS) + Intravenous corticosteroids Days 4-30 SIS + Budesonide 9 mg Days 31-45 SIS + Budesonide 6 mg Days 46-90 SIS + Budesonide 3 mg Days 90 onwards SIS1

Budesonide 3Mg Capsule: Budesonide capsule in place of prednisone (standard of care)
Eligibility criteria:
Inclusion Criteria:

Female or male subjects aged 21-75 years old
Received a primary liver transplant within 4 days of enrollment

Exclusion Criteria:

Received previous organ transplants
Undergoing multiple organ transplants
Recipients with advanced fibrosis in graft
Treatment plan for subject includes receiving immunosuppressant therapy other than standard immune suppression (SIS) as per University of Cincinnati LT immune suppression protocol (UC-ISP).
Inability to take enteral (orally or by tube feed) medications by day 4 post-transplant
Subjects with diabetes mellitus prior to transplant (diabetes mellitus defined as use of hypoglycemic agents or HbA1c > 6.4 prior to transplant)
Subjects who have any severe medical condition requiring acute or chronic treatment that in the investigator's opinion would interfere with study participation.
Subjects who have been exposed to an investigational therapy within 30 days prior to enrollment or 5 half-lives on the investigational product, whichever is greater.
Subjects in which concomitant use of medications which are inhibitors of CYP3A4 (such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin) cannot be avoided during the study period.
Pregnant females
Diminished mental capacity to consent for the study as determined by attending on the record.
Intervention: Prednisone
Trial phase: Phase 2
ATC code: A07EA03 | H02AB07
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Standard of Care Controls that received

Time post Liver Transplantation Immunosuppressive therapy Days 0-3 Standard immune suppression (SIS) + Intravenous corticosteroids Days 4-30 SIS + Prednisone 15-60 mg Days 31-45 SIS + Prednisone 10 mg Days 46-90 SIS + Prednisone 2.5 to 7.5 mg Days 90 onwards SIS
Eligibility criteria:
Inclusion Criteria:

Female or male subjects aged 21-75 years old
Received a primary liver transplant within 4 days of enrollment

Exclusion Criteria:

Received previous organ transplants
Undergoing multiple organ transplants
Recipients with advanced fibrosis in graft
Treatment plan for subject includes receiving immunosuppressant therapy other than standard immune suppression (SIS) as per University of Cincinnati LT immune suppression protocol (UC-ISP).
Inability to take enteral (orally or by tube feed) medications by day 4 post-transplant
Subjects with diabetes mellitus prior to transplant (diabetes mellitus defined as use of hypoglycemic agents or HbA1c > 6.4 prior to transplant)
Subjects who have any severe medical condition requiring acute or chronic treatment that in the investigator's opinion would interfere with study participation.
Subjects who have been exposed to an investigational therapy within 30 days prior to enrollment or 5 half-lives on the investigational product, whichever is greater.
Subjects in which concomitant use of medications which are inhibitors of CYP3A4 (such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin) cannot be avoided during the study period.
Pregnant females
Diminished mental capacity to consent for the study as determined by attending on the record.
Intervention: CID 12303048
Trial phase: Phase 4
ATC code: S03AA04
SMILES: NC(=NCCCCCCN=C(N)N=C(N)Nc1ccc(Cl)cc1)N=C(N)Nc1ccc(Cl)cc1.O=C(O)C(O)C(O)C(O)C(O)CO.O=C(O)C(O)C(O)C(O)C(O)CO
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 59
Group description: Patients to receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.

4% Chlorhexidine Gluconate: Patients will receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
Eligibility criteria:
Inclusion Criteria:

Undergoing hysteroscopy
Gynecologic dilation & curettage
Endometrial ablation
Essure without concomitant laparoscopy

Exclusion Criteria:

Pregnant
Have a history of atopic dermatitis, vaginal irritation, allergic reactions, or anaphylaxis to chlorhexidine gluconate or povidone iodine.
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Patients assigned to chlorprocaine received a single spinal injection of 40 mg of chloroprocaine PF. (other name: pure Nesacaine MPF 3% in a total volume of 2ml)
Eligibility criteria:
Inclusion Criteria:

ASA classification II or III females
Age: 18-45 years old
BMI ≤ 50 kg/m2
Singleton pregnancy
Simple prophylactic cervical cerclage
Planning neuraxial anesthesia

Exclusion Criteria:

Abdominal and complex cervical cerclage (e.g. bulging bag)
Contraindication to neuraxial anesthesia
Known hypersensitivity to chloroprocaine (a.k.a. Ester allergy), paraaminobenzoic acid (PABA) or bupivacaine (a.k.a. Amide allergy)
Pseudocholinesterase deficiency
Concomitant use with ergot-type oxytocic drugs
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Patients assigned to bupivacaine received a single spinal injection of 7.5 mg of bupivacaine. (other name: pure Sensorcaine 0.75% diluted with normal saline to a total volume of 2ml).
Eligibility criteria:
Inclusion Criteria:

ASA classification II or III females
Age: 18-45 years old
BMI ≤ 50 kg/m2
Singleton pregnancy
Simple prophylactic cervical cerclage
Planning neuraxial anesthesia

Exclusion Criteria:

Abdominal and complex cervical cerclage (e.g. bulging bag)
Contraindication to neuraxial anesthesia
Known hypersensitivity to chloroprocaine (a.k.a. Ester allergy), paraaminobenzoic acid (PABA) or bupivacaine (a.k.a. Amide allergy)
Pseudocholinesterase deficiency
Concomitant use with ergot-type oxytocic drugs
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 18
Group description: A single injection of liposomal bupivacaine: mixture of 20 mL liposomal bupivacaine, 20 mL 0.25% bupivacaine, and 10 mL sterile saline (50 mL total), will be delivered in the intercostal space during VATS (with a 178 mm, 22 gauge needle, at ribs 3-8).

Liposomal bupivacaine injection: A single injection of liposomal bupivacaine is administered at the time of SSRF, directly to the fracture site via VATS
Eligibility criteria:
Inclusion Criteria:

Patients undergoing SSRF at Denver Health Medical Center

Exclusion Criteria:

Allergy or hypersensitivity to bupivacaine
Pregnancy
Incarceration
Age < 18 years
Indwelling continuous thoracic epidural analgesia
Intervention: Nitroglycerin
Trial phase: Phase 4
ATC code: C01DA02 | C01DA52 | C05AE01
SMILES: O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 17
Group description: Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes

Nitrostat 0.4Mg Sublingual Tablet: Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes, and only if systolic blood pressure > 100 mmHg.
Eligibility criteria:
Inclusion Criteria:

Over the age of 18 years
Presentation consistent with esophageal food impaction
Ability to swallow a small volume of liquid.

Exclusion Criteria:

Intractable vomiting
Hemodynamic instability or SBP <100 mmHg
Concern for or evidence of significant airway compromise
Concern for or evidence of esophageal perforation,
Concern for or evidence of coronary ischemia
Presentation > 12 hours since onset.
Intervention: Zolpidem Tartrate
Trial phase: Phase 4
SMILES: Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.O=C(O)C(O)C(O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Zolpidem Tartrate: Zolpidem tartrate 5 mg capsule one per night taken for 7 nights
Eligibility criteria:
Inclusion Criteria:

Age 21-79 years old
HFrEF, EF ≤ 45% (by echocardiography)
NYHA functional class I to III
Able to give written consent
On goal-directed medical therapy for HF, with stable dosing of HF medications for 2 weeks prior to enrollment
No hospitalizations for HF within the past month
Positive response to experiencing any of the following sleep-related symptoms at least once a week:
Difficulty falling asleep
Waking up during the night and having difficulty getting back to sleep
Waking up too early in the morning and being unable to get back to sleep.

Exclusion Criteria:

Use of sedative-hypnotics, anxiolytic, or benzodiazepines within the previous 2 weeks
Current treatment with other sedating medications such as opioids
On therapy for pharmacological therapy for depression
History of alcohol/drug dependence
History of liver disease, HIV, or severe COPD
On Thorazine
Current use of ketoconazole
Current use of tricyclic antidepressants
Current use of macrolide antibiotics
Current use of anticonvulsant medications
Pregnancy. A urine pregnancy test will be performed to exclude pregnancy in potential subjects.
Intervention: Lasmiditan
Trial phase: Phase 1
ATC code: N02CC08
SMILES: CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 20
Group description: Lasmiditan administered orally, alone
Eligibility criteria:
Inclusion Criteria:

Are healthy males or females (of non-child bearing potential), as determined by medical history and physical examination
Have a body mass index of 19.0 to 35.0 kilograms per meter squared (kg/m²) inclusive

Exclusion Criteria:

Have known allergies to lasmiditan, topiramate, related compounds or any components of the formulation of lasmiditan or topiramate
Have an abnormal supine blood pressure, defined as systolic blood pressure less than (<) 90 or great (>) 140 millimeters of mercury (mmHg) or diastolic blood pressure <60 or >90 mmHg at screening
Have known or ongoing psychiatric disorders considered clinically significant by the investigator or demonstrate suicidal ideation on the Columbia Suicide Severity Rating Scale (C-SSRS)
Have a clinically significant abnormality in the neurological examination
Have current or a history of orthostatic hypotension (>20-mmHg drop in systolic blood pressure, or >10-mmHg drop in diastolic blood pressure) with or without dizziness and/or syncope at screening or admission to the Clinical Research Unit (CRU) upon repeat testing
Have an estimated glomerular filtration rate using Modification of Diet in Renal Disease <60 milliliter per minute (mL/min) per 1.73 meter squared (m²)
Have a history of glaucoma
Have a history of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
Intervention: Propranolol
Trial phase: Phase 4
ATC code: C07AA05 | C07BA05 | C07FX01
SMILES: CC(C)NCC(O)COc1cccc2ccccc12
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 22
Group description: Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions

Propranolol: Participants will take one dose of Propranolol (40mg IR) on two separate occasions.
Eligibility criteria:
Inclusion Criteria:

Between the ages of 18 and 55
Generally healthy
Right-handed
Smoke >= 5 cigarettes/day of a brand delivering 0.5 mg nicotine (FTC method)
Have been smoking regularly for >= 1 year, with a stable smoking pattern over the past 6 months
Have an expired CO concentration of >= 10 ppm or urinary cotinine > 100 ng/ml
Are able to identify at least 4 smoking and 4 non-smoking enviornments

Exclusion Criteria:

Inability to attend all required sessions
Significant health problems that would interfere with completion of study procedures
Presence of conditions that would make MRI unsafe (e.g. pacemaker)
Presence of exclusionary psychopathology based on MINI interview (current alcohol/substance use disorder moderate or severe pmild is allowable], any history of bipolar disorder or psychosis). Individuals in early remission from substance use disorder (not in a controlled environment) may also be allowed at the PIs discretion
Current use of psychoactive medications per self-report or urine screen. Certain prescribed medications are allowable at the PI's discretion if appropriate documentation (e.g. copy of prescription or physician letter) is provided
Positive breath alcohol concentraiton Pregnant, breastfeeding, or planning to become pregnant during the course of study
Problems with vision that cannot be corrected with contacts or glasses
Current regular use of smokeless tobacco, smoking cessation medications or non-combustible nicotine products (e.g. e-cigarettes)
Plans to alter smoking pattern (e.g. reduction, uptake, cessation) during course of study
Current use of beta-adrenergic medication
Systolic blood pressure < 90 mmHg or diastolic blood pressure < 60 mmHg (sitting or standing)
Low resting heart rate (< 60 beats per minute)
Abnormal EKG
Presence of severe anemia (per complete blood count)
Presence of electrolyte imbalance that could impact blood pressure (per metabolic panel)
Presence of any other contraindications for propranolol (e.g. cardiovascular disease, bronchial asthma, prior allergic reaction)

Note that the above criteria reflect general guidelines for decision-making, but ultimate determinations are left to the discretion of the study physician. Presence of minor (e.g. asymptomatic bradycardia in the range of 50-60 in an otherwise healthy adult) or transient (e.g. electrolyte imbalance readily addressed via changes in fluid intake) may still be deemed eligible to participate.